Enteric Combination Therapy for Refractory Constipation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for constipation do not effectively address the underlying mechanism of the condition, which is believed to be an infection of the gut flora by specific bacterial agents producing bioactive substances, leading to incomplete or variable responses in patients.
Innovation Solution
A composition comprising anti-clostridial agents such as vancomycin, vancomycin derivatives, aminoglycosides, nitroimidazoles, and opioid blocking agents, administered orally or via enema/suppository, to target and suppress the infective agents causing constipation, combined with prokinetic agents to enhance gut motility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional laxatives and dietary fiber are used to treat constipation, then bowel movement frequency may increase temporarily, but the underlying infective mechanism remains untreated leading to variable and incomplete responses
Solution Approach 1:
The patent combines multiple anti-clostridial agents (vancomycin, metronidazole, rifaximin) with opioid blocking agents (naloxone, methyl naltrexone) and prokinetic agents into a single comprehensive treatment regimen. This merging of multiple therapeutic mechanisms addresses both the infective cause (Clostridium difficile overgrowth) and the functional consequence (opioid-mediated motility inhibition), thereby improving treatment reliability while managing complexity through coordinated action
Solution Approach 2:
The treatment protocol functions as a composite therapeutic approach, integrating antibiotics with different mechanisms of action (cell wall synthesis inhibition, DNA damage, protein synthesis inhibition) alongside opioid antagonists and prokinetic agents. This composite strategy targets multiple pathogenic mechanisms simultaneously, ensuring more reliable outcomes compared to single-agent therapies
2Reliability
If multiple anti-clostridial agents are combined with opioid blocking agents, then treatment effectiveness improves by addressing both infection and motility, but the treatment regimen becomes more complex
Solution Approach 1:
The complex treatment regimen is segmented into distinct functional components: anti-clostridial agents (vancomycin, metronidazole, rifaximin) targeting the infective mechanism, opioid blocking agents (naloxone, methyl naltrexone) addressing motility inhibition, and prokinetic agents enhancing bowel movement. This segmentation allows each component to be optimized for its specific function while collectively improving treatment response consistency
Solution Approach 2:
The patent introduces opioid blocking agents as intermediary substances that mediate between the infective mechanism and the functional outcome. These agents block opioid receptors in the gut, preventing opioid-mediated motility inhibition caused by Clostridium difficile toxins, thereby bridging the gap between eliminating infection and restoring normal bowel function
3Quantity of substance
If fiber intake is increased to treat constipation, then bowel bulk increases, but this does not address the root cause and may worsen symptoms in infected bowel flora
Solution Approach 1:
The patent converts the harmful effect of Clostridium difficile overgrowth into a diagnostic and therapeutic opportunity. By identifying constipation as potentially caused by C. diff infection rather than simple dietary insufficiency, the treatment uses anti-clostridial agents to eliminate the pathogen, thereby converting a harmful infectious process into a treatable condition with specific targeted therapy
Solution Approach 2:
Instead of following the conventional approach of increasing fiber to treat constipation, the patent inverts the logic by first eliminating the infective cause (Clostridium difficile) that may be preventing normal bowel function. This inversion reveals that treating the underlying infection rather than the symptomatic fiber deficiency leads to more effective and sustainable resolution of constipation
Data Source
AI summary
There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.